

From: [Neelam Davis](#)
To: [Pharmacy Services](#)
Subject: Zegalogue Oral Testimony
Date: Tuesday, September 7, 2021 9:55:52 AM
Attachments: [ART-1758_Rev A_Dasiglucagon SD Value Dossier 2021_FINAL_032521.pdf](#)
[MED-GL-ZEG-2100002_SRL_State Formulary Review ZEGALOGUE \(dasiglucagon\) injection.pdf](#)

Hello State of Nevada DHCFP-

At the upcoming September 23, 2021 annual review meeting, we see on the agenda that anti-hypoglycemics class of drugs is to be reviewed with no changes. We would like to request 3 minutes for oral testimony on Zegalogue (dasiglucagon), our glucagon analog which was FDA approved earlier this year in March 2021. Please see attached our written testimony and AMCP dossier for Zegalogue. We have not been able to find specific information on how to register to provide oral testimony during the Sept 23rd meeting. Please contact Jean Ritter, National Account Director for Zealand Pharma, with instructions on how to register for oral testimony. Her email address is jritter@zealandpharma.com, and her cell phone is (602) 312-3243.

Thank you for your assistance.

Sincerely,
Medical Information
Zealand Pharma U.S., Inc.